Pfizer reports a drug-related death in tofacitinib trial

04/21/2011 | Wall Street Journal, The

Pfizer confirmed that one of four deaths during a clinical study of tofacitinib, a drug candidate for rheumatoid arthritis, was related to the drug. The company said tofacitinib-related mortality across several trials "is within the range of rates reported for biologic therapies" for the condition. Pfizer aims to market tofacitinib as an alternative to infused or injected treatments, such as Abbott Laboratories' Humira.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY